Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Cash (2020 - 2025)

Historic Change in Cash for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$2.3 million.

  • Maxcyte's Change in Cash fell 30576.58% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.0 million, marking a year-over-year decrease of 9638.91%. This contributed to the annual value of -$18.6 million for FY2024, which is 15254.37% down from last year.
  • Latest data reveals that Maxcyte reported Change in Cash of -$2.3 million as of Q3 2025, which was down 30576.58% from -$8.2 million recorded in Q2 2025.
  • Maxcyte's 5-year Change in Cash high stood at $192.0 million for Q1 2022, and its period low was -$130.6 million during Q2 2022.
  • Over the past 5 years, Maxcyte's median Change in Cash value was -$4.5 million (recorded in 2025), while the average stood at -$304357.9.
  • Examining YoY changes over the last 5 years, Maxcyte's Change in Cash showed a top increase of 22515.49% in 2021 and a maximum decrease of 40924.19% in 2021.
  • Quarter analysis of 5 years shows Maxcyte's Change in Cash stood at -$11.2 million in 2021, then tumbled by 185.55% to -$32.0 million in 2022, then soared by 91.66% to -$2.7 million in 2023, then plummeted by 240.49% to -$9.1 million in 2024, then soared by 75.18% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$8.2 million for Q2 2025, and -$4.5 million during Q1 2025.